8-K current report · filed Oct 21, 2026

Inmune Bio, Inc. (INMB) 8-K Current Report: October 21, 2026

Item 8.01Item EX-99.1Item EX-99.2Item EX-99.3Item 7.01INMB overview

Short answer

Inmune Bio, Inc. (INMB) filed an 8-K current report with the SEC on October 21, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item EX-99.3 (Exhibit EX-99.3), Item 7.01 (Regulation FD Disclosure). Investor presentation furnished as Exhibit 99.3 for use in upcoming company presentations.

Inmune Bio, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Investor presentation furnished as Exhibit 99.3 for use in upcoming company presentations
  • Presentation may provide supplementary information on INmune Bio’s strategy, programs, or outlook

Item 8.01 · Other Events

  • Uniphar agreement establishes infrastructure for international access, distribution and commercialization of Ebstrocel
  • Pre-MAA package submitted to UK MHRA for Ebstrocel, advancing regulatory review toward potential UK authorization
  • Ebstrocel targets RDEB, a rare inherited skin disorder, supporting expansion beyond development-stage activities
  • Exhibit 99.1 and 99.2 press releases contain the substantive commercial and regulatory details

Item EX-99.1 · Exhibit EX-99.1

  • Master Services Agreement with Uniphar establishes international access, distribution and commercialization infrastructure for Ebstrocel
  • Initial strategy: named-patient access in selected European and MENA markets before local marketing approvals
  • Potential services include regulatory assessments, market access, distribution, site onboarding, pharmacovigilance and order-to-cash
  • Capital-efficient outsourcing reduces need for country-by-country commercial buildout, but revenue remains contingent on regulatory and reimbursement progress
  • Ebstrocel remains investigational, with UK MHRA MAA planned for 2026 and EU EMA submission planned for 2027

Item EX-99.2 · Exhibit EX-99.2

  • Final pre-MAA package submitted to UK MHRA on October 20, 2026 for Ebstrocel in RDEB
  • Full UK marketing application targeted for early February 2027, potentially advancing approval by approximately six weeks
  • MHRA response expected three to six months after submission, subject to validation and review
  • U.S. BLA submission planned for Q2 2027, with traditional or accelerated approval under consideration
  • Regulatory milestones remain uncertain, with funding, manufacturing, and approval risks still material to investors

Item EX-99.3 · Exhibit EX-99.3

  • Investor presentation highlights two late-stage platforms: Ebstrocel for RDEB and XPro1595 for inflammation-driven diseases
  • Ebstrocel UK MAA targeted February 2027, potential approval mid-2027, with U.S. BLA planned Q2 2027
  • Mission EB showed 27.5% itch reduction at month six, but primary skin-score endpoint failed at month three
  • Uniphar agreement enables named-patient Ebstrocel access in selected European and MENA markets before approval
  • XPro1595 strategy shifts toward TNF-driven rare diseases, potentially enabling smaller, shorter trials than Alzheimer’s development

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Inmune Bio, Inc. 8-K filings

Get the next INMB 8-K as it lands

Follow INMB for push alerts, or ask the research agent what this filing means.